is tirzepatide a glp 1 Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs Systemic effects of tirzepatide dually

A study of 27 obese women with PCOS who had not responded to lifestyle interventions found that low-dose semaglutide (0.5 mg weekly) produced a mean weight loss of 7.6 kg in just 12 weeks

#AddictionMedicine #OUD #Buprenorphine #PrecisionMedicine #BehavioralHealth #PredictablyHuman #DigitalHealth #PublicHealth #AddictionTreatment #JAMA #MOUD To view or add a comment, sign in A recent Psychology Today article revisits the origins of methadone maintenance treatment (MMT) and reinforces what we see in opioid treatment programs every day: opioid use disorder (OUD) is a chronic medical condition, not a moral failing

Studies indicate that patients combining GLP-1 therapy with 23 sessions of progressive resistance training per week lose 812 additional pounds over 6 months compared to exercise-free groups

People eat significantly less

Favorable outcomes were higher for individuals with emphysema predominantly in the upper lobe with low baseline exercise capacity

Less Common: Stinging, itching, or sensitivity to sunlight